Synergistic Neuromodulation and Stellate Ganglion Block in Depression: A Neuroimmune Framework

Abstract

Background: Major depressive disorder (MDD) is a leading cause of global disability, with many patients remaining resistant to standard pharmacologic and psychotherapeutic treatments. Increasing evidence implicates dysfunctional neural circuitry, autonomic imbalance, and neuroimmune dysregulation in the pathophysiology of MDD. A novel therapeutic strategy combining Stanford Neuromodulation Therapy (SNT) with stellate ganglion block (SGB) may target these interacting systems and potentially improve treatment outcomes in patients with MDD.

Objective:This commentary aims to review the available clinical evidence and mechanistic rationale for combining SNT with SGB in the treatment of major depressive disorder (MDD), a combination that may produce synergistic therapeutic effects.Results: The combination of SNT + SGB was associated with more rapid and greater symptom reduction compared with either monotherapy, with favorable tolerability reported across two clinical studies. Mechanistically, SNT engages fronto-cingulate circuitry, modulates glial–immune signaling, and enhances parasympathetic tone. In contrast, SGB reduces sympathetic outflow and attenuates pro-inflammatory mediators, including IL-6. These complementary effects likely converge on shared neuroimmune pathways, producing synergistic antidepressant outcomes.Conclusion: Integrating cortical neuromodulation with autonomic regulation represents a coherent neuroimmune strategy for treatment-resistant MDD. Combined SNT + SGB may enhance antidepressant efficacy and durability, warranting validation in larger biomarker-informed trials.